help
help > RE: ANCOVA - contrast / hypothesis testing
Dec 19, 2019 07:12 AM | Andrew Zalesky
RE: ANCOVA - contrast / hypothesis testing
Hi Athina,
1. Design matrix (b) is rank deficient and will give you an error/warning. Design matrix (a) is the correct one. Matrix (a) with the contrast given will test whether patients have lower connectivity compared to HC, while controlling for the effect of inflammation.
2. I don't fully follow your question. The contrast of [0 0 -1] will test for a negative correlation between FC and inflammation, while controlling for the effect of diagnosis. Yes - it will also technically "control" for the intercept, but you would generally not say that the intercept is controlled for.
3. The GLM inherent to the NBS is no different from the standard GLM. So if you would demean in a standard GLM, you would be justified in doing it for the NBS. The NBS does not use any kind of special GLM. In general, if you include the intercept term, it does not matter if you demean FC or the inflammation score. Log-transformation is not equivalent to de-meaning and log-transformation could indeed change the results.
4. Yes - the result can be different if you remove certain regions beforehand. If you remove regions, then you won't be able to detect effects at these regions. So clearly the results can change.
Andrew
Originally posted by Athina Aruldass:
1. Design matrix (b) is rank deficient and will give you an error/warning. Design matrix (a) is the correct one. Matrix (a) with the contrast given will test whether patients have lower connectivity compared to HC, while controlling for the effect of inflammation.
2. I don't fully follow your question. The contrast of [0 0 -1] will test for a negative correlation between FC and inflammation, while controlling for the effect of diagnosis. Yes - it will also technically "control" for the intercept, but you would generally not say that the intercept is controlled for.
3. The GLM inherent to the NBS is no different from the standard GLM. So if you would demean in a standard GLM, you would be justified in doing it for the NBS. The NBS does not use any kind of special GLM. In general, if you include the intercept term, it does not matter if you demean FC or the inflammation score. Log-transformation is not equivalent to de-meaning and log-transformation could indeed change the results.
4. Yes - the result can be different if you remove certain regions beforehand. If you remove regions, then you won't be able to detect effects at these regions. So clearly the results can change.
Andrew
Originally posted by Athina Aruldass:
Hello Andrew - thank you very much for your
previous input ! Much to my dismay, I indeed have to put any
further analyses on embargo (after some discussion with my
Supervisor on my initial set of findings...).
I have some other questions for you now re the simple cases - mainly to gain a more understanding of what the contrast is doing -
(1) When testing for group differences (2 groups) / main group effect whilst controlling for inflammation - what is the difference between design matrices (a) and (b) below ? Are they testing for the same hypothesis ie FC is Lower in Patient group when controlling for inflammation ? Is design (a) incorrect when testing for this hypothesis - is this testing for negative correlation between FC and Group, how would you interpret this association ?
design matrix (a)
1 1 0.3
1 0 2.2
1 1 0.3
contrast : [0 -1 0] , t-test
cols : intercept ; Group - HC(0) and Pts(1) ; inflammation
design matrix (b)
1 1 0 0.3
1 0 1 2.2
1 1 0 0.3
contrast : [0 1 -1 0], t-test
cols : intercept ; HC ; Pts ; inflammation
(2) I understand that in linear model the intercept = dependent variable when explanatory variable = 0. In my ANCOVA design matrix below for example, when testing for the effect on inflammation on FC, the intercept models global mean FC when inflammation is 0 - true ? Also, with contrast notation [0 0 -1] for below - is this controlling for group AND global mean FC ?? What does setting intercept contrast to 0 denote / doing ?
1 1 0.3
1 0 2.2
1 1 0.3
cols : intercept ; Group - HC(0) and Pts(1) ; inflammation
(3) Why and when is demeaning a variable (dependent and/or explanatory) necessary for NBS ? Is demeaning here equivalent to mean centering eg. standard scoring, Fisher r-z transformation, log transformation ? My FC matrices are already r-z transformed but the inflammation index is in mg/L ie both not in comparable scale - would/ should this have any effect on output ... ?? I repeated my analyses with log-transformed inflammation - did not see any difference ie still no significant network ?
(4) I would also like to try restricting testing to specific ROIs / a functional module. Based on you explanation below to another question on the forum - you have indicated that this would reduce number of multiple comparisons. Could this then yield a different outcome compared to when inputing full connectivity matrix ? If so / not - why ?
"If a connection is 0 for all subjects, then the NBS will automatically ignore that connection during statistical testing.
In other words, if the connectivity value for a given connection is zero in all connectivity matrices, that specific connection is ignored by default and the number of multiple comparisons reduced accordingly."
Hope my queries make sense - sorry, please and many thanks again - Athina.
I have some other questions for you now re the simple cases - mainly to gain a more understanding of what the contrast is doing -
(1) When testing for group differences (2 groups) / main group effect whilst controlling for inflammation - what is the difference between design matrices (a) and (b) below ? Are they testing for the same hypothesis ie FC is Lower in Patient group when controlling for inflammation ? Is design (a) incorrect when testing for this hypothesis - is this testing for negative correlation between FC and Group, how would you interpret this association ?
design matrix (a)
1 1 0.3
1 0 2.2
1 1 0.3
contrast : [0 -1 0] , t-test
cols : intercept ; Group - HC(0) and Pts(1) ; inflammation
design matrix (b)
1 1 0 0.3
1 0 1 2.2
1 1 0 0.3
contrast : [0 1 -1 0], t-test
cols : intercept ; HC ; Pts ; inflammation
(2) I understand that in linear model the intercept = dependent variable when explanatory variable = 0. In my ANCOVA design matrix below for example, when testing for the effect on inflammation on FC, the intercept models global mean FC when inflammation is 0 - true ? Also, with contrast notation [0 0 -1] for below - is this controlling for group AND global mean FC ?? What does setting intercept contrast to 0 denote / doing ?
1 1 0.3
1 0 2.2
1 1 0.3
cols : intercept ; Group - HC(0) and Pts(1) ; inflammation
(3) Why and when is demeaning a variable (dependent and/or explanatory) necessary for NBS ? Is demeaning here equivalent to mean centering eg. standard scoring, Fisher r-z transformation, log transformation ? My FC matrices are already r-z transformed but the inflammation index is in mg/L ie both not in comparable scale - would/ should this have any effect on output ... ?? I repeated my analyses with log-transformed inflammation - did not see any difference ie still no significant network ?
(4) I would also like to try restricting testing to specific ROIs / a functional module. Based on you explanation below to another question on the forum - you have indicated that this would reduce number of multiple comparisons. Could this then yield a different outcome compared to when inputing full connectivity matrix ? If so / not - why ?
"If a connection is 0 for all subjects, then the NBS will automatically ignore that connection during statistical testing.
In other words, if the connectivity value for a given connection is zero in all connectivity matrices, that specific connection is ignored by default and the number of multiple comparisons reduced accordingly."
Hope my queries make sense - sorry, please and many thanks again - Athina.
Threaded View
| Title | Author | Date |
|---|---|---|
| Athina Aruldass | Dec 6, 2019 | |
| Athina Aruldass | Dec 18, 2019 | |
| Andrew Zalesky | Dec 19, 2019 | |
| Athina Aruldass | Jan 6, 2020 | |
| Andrew Zalesky | Jan 6, 2020 | |
| Athina Aruldass | Dec 10, 2019 | |
| Andrew Zalesky | Dec 13, 2019 | |
| Athina Aruldass | Dec 9, 2019 | |
| Andrew Zalesky | Dec 7, 2019 | |
